Gufic Biosciences Reports Q2 FY27 Unaudited Results; Appoints Dr. Reeta Shah as Director
Gufic Biosciences reported its Q2 FY27 results. Standalone Q2 revenue was ₹289.53 crore, with a net profit of ₹23.49 crore. Consolidated Q2 revenue stood at ₹289.40 crore, with a net profit of ₹23.47 crore. The company also appointed Dr. Reeta Shah as an Additional Director, effective December 1, 2026.
The financial results show growth, and the appointment of a new director can positively influence strategic decisions. However, the impact is considered medium as it's a routine financial disclosure and a director appointment without immediate major strategic shifts.
The company reported positive financial results with increased revenue and profit for the quarter and half-year. The appointment of an experienced director also adds to the positive outlook.
Gufic Biosciences Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported total income of ₹28,952.62 lakh (₹289.53 crore) for the quarter and ₹55,080.17 lakh (₹550.80 crore) for the half-year on a standalone basis.
On a consolidated basis, the total income for the quarter was ₹28,939.77 lakh (₹289.40 crore) and for the half-year was ₹55,067.32 lakh (₹550.67 crore). The net profit for the quarter stood at ₹2,348.86 lakh (₹23.49 crore) standalone and ₹2,346.89 lakh (₹23.47 crore) consolidated. For the half-year, the net profit was ₹4,594.91 lakh (₹45.95 crore) standalone and ₹4,578.17 lakh (₹45.78 crore) consolidated.
The Board of Directors also approved the appointment of Dr. Reeta Shah as an Additional Director (Non-Executive Independent Director) for a term of 5 years, effective from December 01, 2026, subject to shareholder approval. Dr. Shah is a Chartered Accountant with a Ph.D. in Finance from IIT Bombay and brings over 38 years of experience in finance, education, and administration. She is not related to any existing director of the company.
The Board meeting commenced at 5:00 p.m. and concluded at 06:35 p.m. on November 14, 2026.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.